Sign In
Buy SRRK
$47.30
-1.70 (-3.46%)
At Close: Jul 31, 2026
Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting
08:00am, Thursday, 31'st Oct 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic dis
Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering
08:00am, Tuesday, 22'nd Oct 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA),
Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross?
10:55am, Monday, 21'st Oct 2024
Scholar Rock Holding Corporation (SRRK) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, SRRK's 50-day simple moving average c
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 18'th Oct 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardio
Here's Why Everybody's Talking About Scholar Rock Right Now
05:38am, Wednesday, 09'th Oct 2024
Successful clinical-trial results recently made Scholar Rock one of the stock market's top performers.
Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants
11:08pm, Tuesday, 08'th Oct 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA),
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal
12:03pm, Tuesday, 08'th Oct 2024
Scholar Rock stock skyrockets as the late-stage study of the investigational therapy, apitegromab, to treat spinal muscular atrophy meets the primary goal.
Scholar Rock (SRRK) Shares Surge on Successful SMA Drug Trial
10:10pm, Monday, 07'th Oct 2024
Shares of Scholar Rock Holding Corp. (SRRK, Financial) soared by 335% as their candidate drug for spinal muscular atrophy (SMA), apitegromab, achieved the primary endpoint in a Phase 3 trial. The posi
Scholar Rock: SMA Program Strides Forward With Positive Clinical Data
05:29pm, Monday, 07'th Oct 2024
Apitegromab met the primary endpoint in its phase 3 SAPPHIRE study for spinal muscular atrophy, setting up BLA & MAA filings in Q1 2025. Apitegromab is the first treatment targeting muscle fiber atrop
Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:09pm, Monday, 07'th Oct 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA),
Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher
12:00pm, Monday, 07'th Oct 2024
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points on Monday.
Scholar Rock's stock soars more than 200% on positive trial of treatment for spinal muscular atrophy
08:20am, Monday, 07'th Oct 2024
The Phase 3 trial of Apitegromab showed statistically significant improvement in motor function.
Scholar Rock to Participate in Upcoming Investor Conferences
08:00am, Thursday, 29'th Aug 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic dis
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
12:00pm, Monday, 26'th Aug 2024
While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contender
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 12'th Jul 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardio
